Keyun Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Keyun Tang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Hanlin Zhang
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing
12 shared publications - Qiuning Sun
Department of Dermatology, Peking Union Medical College Hospital, Beijing, China
9 shared publications - Yuanzhuo Wang
Department of Dermatology Peking Union Medical College Hospital Beijing China
6 shared publications - Hongzhong Jin
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
5 shared publications - Rouyu Fang
Department of Dermatology Peking Union Medical College Hospital Beijing China
5 shared publications Qingyue Zheng
Department of Dermatology Peking Union Medical College Hospital Beijing China
3 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1226
Bupivacaine-Loaded PLGA Nanoparticles for Long-Term Management of Chronic Neuropathic Pain
Background/Objectives: Chronic neuropathic pain imposes a substantial burden on patients and society, and opioids are unsuitable for long-term use due to their addictive potential. To overcome this limitation, we encapsulated bupivacaine in PLGA nanoparticles to achieve sustained-release analgesia with reduced systemic toxicity. Methods: The analgesic efficacy was evaluated in rat models of chronic compression of the dorsal root ganglion (CCD) and chronic constriction injury (CCI). Nanoparticles were characterized using scanning electron microscopy (SEM) for morphology and size, and X-ray diffraction (XRD) for dispersion. In vivo electrophysiological recordings, including action potentials from DRG neuronal somata and compound action potentials in the sciatic nerve, were performed to investigate peripheral analgesic mechanisms, while plasma bupivacaine concentrations were measured by high-performance liquid chromatography (HPLC). Results: Bupivacaine nanoparticles significantly alleviated mechanical pain in both CCD and CCI rats, but had no effect on thermal pain. They selectively inhibited C-fiber conduction without affecting A-fibers. Importantly, plasma bupivacaine levels remained well below the corresponding toxic thresholds, indicating a favorable safety profile. Conclusions: These findings suggest that bupivacaine-loaded PLGA nanoparticles represent a promising long-term therapeutic option for chronic neuropathic pain management.
- 27 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1226
Open AccessBupivacaine-Loaded PLGA Nanoparticles for Long-Term Management of Chronic Neuropathic Pain
Background/Objectives: Chronic neuropathic pain imposes a substantial burden on patients and society, and opioids are unsuitable for long-term use due to their addictive potential. To overcome this limitation, we encapsulated bupivacaine in PLGA nanoparticles to achieve sustained-release analgesia with reduced systemic toxicity. Methods: The analgesic efficacy was evaluated in rat models of chronic compression of the dorsal root ganglion (CCD) and chronic constriction injury (CCI). Nanoparticles were characterized using scanning electron microscopy (SEM) for morphology and size, and X-ray diffraction (XRD) for dispersion. In vivo electrophysiological recordings, including action potentials from DRG neuronal somata and compound action potentials in the sciatic nerve, were performed to investigate peripheral analgesic mechanisms, while plasma bupivacaine concentrations were measured by high-performance liquid chromatography (HPLC). Results: Bupivacaine nanoparticles significantly alleviated mechanical pain in both CCD and CCI rats, but had no effect on thermal pain. They selectively inhibited C-fiber conduction without affecting A-fibers. Importantly, plasma bupivacaine levels remained well below the corresponding toxic thresholds, indicating a favorable safety profile. Conclusions: These findings suggest that bupivacaine-loaded PLGA nanoparticles represent a promising long-term therapeutic option for chronic neuropathic pain management.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Human Herpesvirus and Pemphigus: An Updated Narrative Review
The association between pemphigus and human herpesvirus (HHV) has been debated for decades. This review comprehensively summarizes current evidence on the epidemiological links, pathogenic hypotheses, and management challenges of HHV infection in pemphigus patients. Epidemiological studies indicate a higher prevalence of HHV infections in pemphigus patients compared to healthy controls. Hypotheses on the potential role of HHV in pemphigus were categorized into three distinct types: a trigger for disease onset, a factor in exacerbation or treatment resistance, or a complication of immunosuppressive therapy. Clinically, while HHV coinfection poses challenges to clinical diagnosis, specific clinical features may facilitate timely identification. Furthermore, empirical antiviral therapies demonstrate efficacy in improving patient outcomes, but standard guidelines are lacked. A clearer understanding of this association between virus and host autoimmunity is essential for optimizing outcomes in patients with pemphigus.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessHuman Herpesvirus and Pemphigus: An Updated Narrative Review
The association between pemphigus and human herpesvirus (HHV) has been debated for decades. This review comprehensively summarizes current evidence on the epidemiological links, pathogenic hypotheses, and management challenges of HHV infection in pemphigus patients. Epidemiological studies indicate a higher prevalence of HHV infections in pemphigus patients compared to healthy controls. Hypotheses on the potential role of HHV in pemphigus were categorized into three distinct types: a trigger for disease onset, a factor in exacerbation or treatment resistance, or a complication of immunosuppressive therapy. Clinically, while HHV coinfection poses challenges to clinical diagnosis, specific clinical features may facilitate timely identification. Furthermore, empirical antiviral therapies demonstrate efficacy in improving patient outcomes, but standard guidelines are lacked. A clearer understanding of this association between virus and host autoimmunity is essential for optimizing outcomes in patients with pemphigus.
- Open Access
- 21 November 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (2) , e16697
Cosmetic Dermatology in Patients With Immune‐Mediated Skin Diseases: A Future Direction
- 21 November 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (2) , e16697
Open AccessCosmetic Dermatology in Patients With Immune‐Mediated Skin Diseases: A Future Direction
- 11 September 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , 1646-1657
Clinical and laboratory features between anti‐TIF1γ dermatomyositis with and without malignancy: 37 case series and a review
We aimed to analyze the clinical profile and malignancy indicators in dermatomyositis (DM) with anti‐transcriptional intermediary factor 1 antibody (anti‐TIF1γ‐Ab). A comparison was made between clinical information of anti‐TIF1γ DM patients with and without malignancy. Additionally, a review of the literature on anti‐TIF1γ DM and malignancy was conducted by searching PubMed and EMBASE databases. In our cohort of 37 patients, 27.0% (10/37) developed malignancy. The timeframe during which these 10 patients developed malignancy ranged from 21 months prior to the diagnosis of DM to 36 months following the diagnosis of DM. Specifically, one patient was diagnosed with breast cancer at the age of 36. Comparing the groups with and without malignancy, we found that age over 65 years (40% vs 7.4%, P = 0.035), a shorter duration from the onset of symptoms to the diagnosis of DM (2.5 vs 10 months, P = 0.003), and higher erythrocyte sedimentation rate (ESR) levels (23 vs 10 mm/h, P = 0.048) were found to be associated with an increased risk of malignancy. Conversely, the presence of Gottron's papules (63% vs 20%, P = 0.029) may suggest a lower likelihood of malignancy. The literature review revealed that the prevalence of myositis‐associated malignancy was 40.7% (340/836), with variations ranging from 19% to 82.9% across different series. In summary, factors such as age over 65 years, a shorter duration between symptom onset and diagnosis of DM, and elevated ESR levels may indicate an increased risk of malignancy in anti‐TIF1γ DM patients.
- 11 September 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (12) , 1646-1657
Clinical and laboratory features between anti‐TIF1γ dermatomyositis with and without malignancy: 37 case series and a review
We aimed to analyze the clinical profile and malignancy indicators in dermatomyositis (DM) with anti‐transcriptional intermediary factor 1 antibody (anti‐TIF1γ‐Ab). A comparison was made between clinical information of anti‐TIF1γ DM patients with and without malignancy. Additionally, a review of the literature on anti‐TIF1γ DM and malignancy was conducted by searching PubMed and EMBASE databases. In our cohort of 37 patients, 27.0% (10/37) developed malignancy. The timeframe during which these 10 patients developed malignancy ranged from 21 months prior to the diagnosis of DM to 36 months following the diagnosis of DM. Specifically, one patient was diagnosed with breast cancer at the age of 36. Comparing the groups with and without malignancy, we found that age over 65 years (40% vs 7.4%, P = 0.035), a shorter duration from the onset of symptoms to the diagnosis of DM (2.5 vs 10 months, P = 0.003), and higher erythrocyte sedimentation rate (ESR) levels (23 vs 10 mm/h, P = 0.048) were found to be associated with an increased risk of malignancy. Conversely, the presence of Gottron's papules (63% vs 20%, P = 0.029) may suggest a lower likelihood of malignancy. The literature review revealed that the prevalence of myositis‐associated malignancy was 40.7% (340/836), with variations ranging from 19% to 82.9% across different series. In summary, factors such as age over 65 years, a shorter duration between symptom onset and diagnosis of DM, and elevated ESR levels may indicate an increased risk of malignancy in anti‐TIF1γ DM patients.
- 14 April 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (9) , 1274-1276
Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies
- 14 April 2024
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (9) , 1274-1276
Erythrodermic dermatomyositis with anti‐TIF1‐γ antibodies
- 19 July 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (11) , 6484-6486
Lupus miliaris disseminatus faciei in a 10‐year‐old child: A case report and literature review
- 19 July 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (11) , 6484-6486
Lupus miliaris disseminatus faciei in a 10‐year‐old child: A case report and literature review
- Open Access
- 1 April 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 407-417
Use of Botulinum Toxin in Treating Rosacea: A Systematic Review
Background: Rosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment. Methods: PubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed. Results: Nine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited. Conclusion: Botulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.
- 1 April 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 407-417
Open AccessUse of Botulinum Toxin in Treating Rosacea: A Systematic Review
Background: Rosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment. Methods: PubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed. Results: Nine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited. Conclusion: Botulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.
- 5 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3446-3447
Understanding and caring for lesbian, gay, bisexual, and transgender patients in dermatologic clinics: A dermatologist’s perspective from China
- 5 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3446-3447
Understanding and caring for lesbian, gay, bisexual, and transgender patients in dermatologic clinics: A dermatologist’s perspective from China
- 3 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (10) , 2560-2565
Botulinum toxin as a double‐edged sword in alopecia: A systematic review
Background: Alopecia is a common disease influencing the quality of life of the patients. Botulinum toxin has been widely employed in cosmetic dermatology and was applied in some clinical trials to treat alopecia.Aims: Hence, We conducted a systematic review to examine the safety and efficacy of using botulinum toxin in treating alopecia.Methods: Cochrane Library, Embase, PubMed, and Web of Science databases were used to search for articles. A PICOS question was formed and the author, year of publication, number of participants, study design, product, dilution and dosing, outcome measurement, findings, side effects, and follow‐up were retrieved. The Oxford Centre for Evidence‐Based Medicine 2011 Levels of Evidence was used as a qualitative indicator to evaluate the levels of evidence.Results: Eleven articles published between 2005 and 2019 were included. 9 of which were about treatment effects and 2 were concerning adverse effects. The total number of the participants was 106, and the number for each article was ranged from 1 to 50. Varying type of outcome measurements was used for the publications. 8 articles were evaluated as Level 4 and 1 was evaluated as Level 5 during the 9 articles with treatment effects.Conclusions: The results showed that botulinum toxin may function as a double‐edged sword and have a low degree of efficacy and safety in treating alopecia. The study may be useful to remind the physicians of adverse effects in clinical practice and pave the way for further research. A larger, randomized, placebo‐controlled study is warranted.
- 3 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (10) , 2560-2565
Botulinum toxin as a double‐edged sword in alopecia: A systematic review
Background: Alopecia is a common disease influencing the quality of life of the patients. Botulinum toxin has been widely employed in cosmetic dermatology and was applied in some clinical trials to treat alopecia.Aims: Hence, We conducted a systematic review to examine the safety and efficacy of using botulinum toxin in treating alopecia.Methods: Cochrane Library, Embase, PubMed, and Web of Science databases were used to search for articles. A PICOS question was formed and the author, year of publication, number of participants, study design, product, dilution and dosing, outcome measurement, findings, side effects, and follow‐up were retrieved. The Oxford Centre for Evidence‐Based Medicine 2011 Levels of Evidence was used as a qualitative indicator to evaluate the levels of evidence.Results: Eleven articles published between 2005 and 2019 were included. 9 of which were about treatment effects and 2 were concerning adverse effects. The total number of the participants was 106, and the number for each article was ranged from 1 to 50. Varying type of outcome measurements was used for the publications. 8 articles were evaluated as Level 4 and 1 was evaluated as Level 5 during the 9 articles with treatment effects.Conclusions: The results showed that botulinum toxin may function as a double‐edged sword and have a low degree of efficacy and safety in treating alopecia. The study may be useful to remind the physicians of adverse effects in clinical practice and pave the way for further research. A larger, randomized, placebo‐controlled study is warranted.
- 16 July 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14017
Public interest in Raynaud's phenomenon: A Google Trends analysis
- 16 July 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e14017
Public interest in Raynaud's phenomenon: A Google Trends analysis